लोड हो रहा है...
Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer
PURPOSE: Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The rates and patterns of trastuzumab use have never been described in a population-based sample. The recent addition of HER2 information to the SEER...
में बचाया:
में प्रकाशित: | J Clin Oncol |
---|---|
मुख्य लेखकों: | , , , , |
स्वरूप: | Artigo |
भाषा: | Inglês |
प्रकाशित: |
American Society of Clinical Oncology
2016
|
विषय: | |
ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966516/ https://ncbi.nlm.nih.gov/pubmed/27069085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.8716 |
टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|